PQQ supplement for thinking and negative symptoms in schizophrenia
Part of Brain & nervous system, Mental health clinical trials.
This trial tests whether a dietary supplement called PQQ (pyrroloquinoline quinone) can improve thinking, memory, and negative symptoms (like lack of motivation) in chronic schizophrenia. It might help because PQQ has antioxidant and anti-inflammatory effects that could protect brain health.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 to 50 years old.
- You must have a schizophrenia diagnosis (per DSM-5) and an active episode (PANSS score ≥ 60).
- Your negative symptoms (like apathy or lack of emotion) must be significant (PANSS negative subscale ≥ 20).
- You must have had schizophrenia for at least 2 years.
- You must be on a stable dose of antipsychotic medication for at least 6 weeks before starting.
- You cannot take antioxidants, anti-inflammatory drugs, or certain other medications within 2 weeks before the trial.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 trial tests whether a “synbiotic” supplement (a mix of probiotics and prebiotics) can reduce symptoms of schizophrenia or schizoaffective disorder. It may help by targeting gut-related immune and inflammation pathways that could affect brain symptoms.
This study tests a new treatment that may help with thinking and memory problems in people with schizophrenia. It is for people whose schizophrenia symptoms are stable and who are already on a steady medication.
This study tests whether a medication called prucalopride can help improve thinking and memory in people with schizophrenia. If you're stable on your current treatment, this trial might offer a new way to address cognitive challenges.
This trial tests if berberine, a natural supplement, can help reduce negative symptoms like lack of motivation or social withdrawal in people with schizophrenia. It may work by affecting the brain and body.
This study tests whether a medication that boosts brain NMDA receptors can improve negative symptoms in schizophrenia, and looks at differences between men and women. It is for people with stable schizophrenia who still have mostly flat mood or low motivation.
This study tests whether a supplement called MitoQ can help people with early-stage psychosis by improving how their cells produce energy. If you are younger and have been treated for psychosis for less than 5 years, this trial may be an option for you.
Hear when a new Schizophrenia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.